Efficacy and safety of tripterygium glycosides in the treatment of hyperthyroidism

Xie, Chunyan; He, Chuanchao; Gao, Jun; Jia, Shulei

doi:10.1097/md.0000000000022282

Cited by 4 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study by Xie et al investigated the anti-hyperthyroidism efficacy and safety of combining tripterygium glycosides with thiamazole or prednisone. 375 The data indicated that involving tripterygium glycosides decreased the exophthalmos, serum-free triiodothyronine, FT4, plasma osteocalcin, and alkaline phosphatase while increasing TSH, SOD, and glutathione peroxidase. Their findings demonstrated that combining tripterygium glycosides and chemical compounds is an efficient treatment against hyperthyroidism.…”

Section: Hyperthyroidismmentioning

confidence: 94%

Multifunctional nanoparticle-mediated combining therapy for human diseases

Li,

Peng,

Zoulikha

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Combining existing drug therapy is essential in developing new therapeutic agents in disease prevention and treatment. In preclinical investigations, combined effect of certain known drugs has been well established in treating extensive human diseases. Attributed to synergistic effects by targeting various disease pathways and advantages, such as reduced administration dose, decreased toxicity, and alleviated drug resistance, combinatorial treatment is now being pursued by delivering therapeutic agents to combat major clinical illnesses, such as cancer, atherosclerosis, pulmonary hypertension, myocarditis, rheumatoid arthritis, inflammatory bowel disease, metabolic disorders and neurodegenerative diseases. Combinatorial therapy involves combining or co-delivering two or more drugs for treating a specific disease. Nanoparticle (NP)-mediated drug delivery systems, i.e., liposomal NPs, polymeric NPs and nanocrystals, are of great interest in combinatorial therapy for a wide range of disorders due to targeted drug delivery, extended drug release, and higher drug stability to avoid rapid clearance at infected areas. This review summarizes various targets of diseases, preclinical or clinically approved drug combinations and the development of multifunctional NPs for combining therapy and emphasizes combinatorial therapeutic strategies based on drug delivery for treating severe clinical diseases. Ultimately, we discuss the challenging of developing NP-codelivery and translation and provide potential approaches to address the limitations. This review offers a comprehensive overview for recent cutting-edge and challenging in developing NP-mediated combination therapy for human diseases.

show abstract

Section: Hyperthyroidismmentioning

confidence: 94%

Multifunctional nanoparticle-mediated combining therapy for human diseases

Li,

Peng,

Zoulikha

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…A previous study has suggested that Tripterygium glycosides can relieve hematuria and proteinuria in immunoglobulin A deposition nephropathy and diabetic nephropathy [ 11 ]. In addition, Tripterygium glycosides can enhance the effect of thiamazole and prednisone in the treatment of hyperthyroidism [ 12 ]. Moreover, Tripterygium glycosides have been used to reduce proteinuria and protect the kidney for more than 20 years [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

The Efficacy of Tripterygium Glycosides Combined with LMWH in Treatment of HSPN in Children

Jin

Wang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. This study aimed to explore the clinical efficacy and relevant mechanism of Tripterygium glycosides combined with low molecular weight heparin calcium (LMWH) in the treatment of Henoch–Schönlein purpura nephritis (HSPN) in children. Methods. 64 cases of children patients with HSPN treated at Qilu Hospital (Qingdao) from January 2015 to May 2020 were selected and randomly divided into the control group and the observation group and 32 cases in each group. Conventional medical treatment was applied in the two groups, besides which the control group was given LMWH while the observation group was given Tripterygium glycosides based on the control group. The clinical efficacy and the indexes of clinical symptoms of the two groups were compared. Immune globulin level, fibrinogen content (FIB), prothrombin time (PT), platelet level (PLT), and activated partial thromboplastin time (APTT) level of the two groups were compared before and after the treatment. Results. The total effective rate in the observation group was significantly higher than that of the control group, and the recurrence rate in the observation group was lower than that in the control group. After treatment, urine red blood cell count and 24 h urine protein were obviously better than those of the control group. There was no statistically significant difference in PT between the two groups of children before and after treatment. The levels of PLT and FIB in the two groups of patients after treatment were significantly lower than before treatment, and the PLT levels in the observation group were lower than those in the control group. Conclusion. The combination of Tripterygium glycosides and LMWH had good clinical effects in the treatment of children with HSPN, and it could improve the clinical symptoms, the mechanism of which might be related to the increase of PT, a decrease of PLT, and the improvement of coagulation function.

show abstract